NCT04992156View on ClinicalTrials.gov

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

March 15, 2022

Study Completion Date

April 15, 2022

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Palbociclib

Palbociclib 125mg/d

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04992156 - Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET | Biotech Hunter | Biotech Hunter